Hollis-Eden included on HHS shortlist for treatment of radiation exposure

New York, June 26 - Hollis-Eden Pharmaceuticals, Inc. said it has been informed by the Department of Health and Human Services that the company's proposal for medical measures to treat people exposed to Acute Radiation Syndrome is "within the competitive range for discussion and further evaluation."

Hollis-Eden is a San Diego-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.